199 related articles for article (PubMed ID: 15076241)
21. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Antoniou T; Park-Wyllie LY; Tseng AL
Pharmacotherapy; 2003 Jan; 23(1):29-43. PubMed ID: 12523458
[TBL] [Abstract][Full Text] [Related]
22. Renal lesions in HIV-1-positive patient treated with tenofovir.
Créput C; Gonzalez-Canali G; Hill G; Piketty C; Kazatchkine M; Nochy D
AIDS; 2003 Apr; 17(6):935-7. PubMed ID: 12660548
[No Abstract] [Full Text] [Related]
23. Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.
Saidenberg-Kermanac'h N; Souabni L; Prendki V; Prie D; Boissier MC
Joint Bone Spine; 2011 May; 78(3):306-8. PubMed ID: 21185214
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir poses risk with didanosine.
AIDS Patient Care STDS; 2003 Jun; 17(6):309. PubMed ID: 12880494
[No Abstract] [Full Text] [Related]
25. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Gatanaga H; Tachikawa N; Kikuchi Y; Teruya K; Genka I; Honda M; Tanuma J; Yazaki H; Ueda A; Kimura S; Oka S
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):744-8. PubMed ID: 16910829
[TBL] [Abstract][Full Text] [Related]
26. Renal tubular dysfunction associated with tenofovir therapy.
Mitra S; Priscilla R; Rajeev K; Sauradeep S; Rajkumar S; Cherian AO
J Assoc Physicians India; 2014 Jul; 62(7):580-2. PubMed ID: 25672029
[TBL] [Abstract][Full Text] [Related]
27. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution.
Gaspar G; Monereo A; García-Reyne A; de Guzmán M
AIDS; 2004 Jan; 18(2):351-2. PubMed ID: 15075563
[No Abstract] [Full Text] [Related]
28. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.
Zimmermann AE; Pizzoferrato T; Bedford J; Morris A; Hoffman R; Braden G
Clin Infect Dis; 2006 Jan; 42(2):283-90. PubMed ID: 16355343
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
Calza L; Trapani F; Tedeschi S; Piergentili B; Manfredi R; Colangeli V; Viale P
Scand J Infect Dis; 2011 Aug; 43(8):656-60. PubMed ID: 21453205
[TBL] [Abstract][Full Text] [Related]
30. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
[TBL] [Abstract][Full Text] [Related]
31. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
Coca S; Perazella MA
Am J Med Sci; 2002 Dec; 324(6):342-4. PubMed ID: 12495304
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
33. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.
Murphy MD; O'Hearn M; Chou S
Clin Infect Dis; 2003 Apr; 36(8):1082-5. PubMed ID: 12684925
[TBL] [Abstract][Full Text] [Related]
34. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
Viganò A; Zuccotti GV; Martelli L; Giacomet V; Cafarelli L; Borgonovo S; Beretta S; Rombolà G; Mora S
Clin Drug Investig; 2007; 27(8):573-81. PubMed ID: 17638398
[TBL] [Abstract][Full Text] [Related]
35. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir.
Callens S; De Roo A; Colebunders R
J Infect; 2003 Oct; 47(3):262-3. PubMed ID: 12963392
[No Abstract] [Full Text] [Related]
36. Tenofovir-related nephrotoxicity: case report and review of the literature.
James CW; Steinhaus MC; Szabo S; Dressier RM
Pharmacotherapy; 2004 Mar; 24(3):415-8. PubMed ID: 15040657
[TBL] [Abstract][Full Text] [Related]
37. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.
Van Rompay KK; Brignolo LL; Meyer DJ; Jerome C; Tarara R; Spinner A; Hamilton M; Hirst LL; Bennett DR; Canfield DR; Dearman TG; Von Morgenland W; Allen PC; Valverde C; Castillo AB; Martin RB; Samii VF; Bendele R; Desjardins J; Marthas ML; Pedersen NC; Bischofberger N
Antimicrob Agents Chemother; 2004 May; 48(5):1469-87. PubMed ID: 15105094
[TBL] [Abstract][Full Text] [Related]
38. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
Callens S; De Schacht C; Huyst V; Colebunders R
J Infect; 2003 Aug; 47(2):188-9. PubMed ID: 12860159
[No Abstract] [Full Text] [Related]
39. Proximal tubular renal dysfunction or damage in HIV-infected patients.
Del Palacio M; Romero S; Casado JL
AIDS Rev; 2012; 14(3):179-87. PubMed ID: 22833061
[TBL] [Abstract][Full Text] [Related]
40. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
